B. Strober, “Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial”, J of Skin, vol. 5, no. 6, p. s52, Nov. 2021.